drug development

Aridis Pharmaceuticals, Inc. is a late-stage clinical development biopharmaceutical company focused on developing novel, differentiated therapies for infectious diseases, including first-in-class anti-infectives for life-threatening viral and bacterial respiratory infections. Its pipeline includes therapeutic monoclonal antibodies and novel anti-infectives derived from its proprietary technology platforms.

clinical developmentMabIgX technology platformmonoclonal antibody discovery and development⅄PEX technology platform

Aurora Oncology is a pre-clinical biotechnology start-up created by scientists and physicians at the University of Colorado Anschutz Medical Campus and Boulder Campus. It is dedicated to developing drugs and diagnostics to treat bladder cancer, bringing discoveries from the research bench to patients with targetable tumors. The company is a member of the SPARK program and has received funding from NIH, the State of Colorado, and CU Innovations.

diagnostics developmenttargeted therapytheranosticsthermal ablation

AVM Biotechnology is a clinical-stage company founded by Theresa Deisher, Ph.D., developing AVM0703, a proprietary formulation of concentrated dexamethasone that permits very high dosing to activate the release and trigger production of the body's gamma delta TCR+ invariant TCR+ bispecific T lymphocytes and Natural Killer T-like immune cells. The company targets cancer, autoimmune syndromes, acute respiratory distress syndrome (ARDS), and infectious diseases.

clinical trialscompassionate use

BalinBac Therapeutics, Inc. is a clinical stage biopharmaceutical development company headquartered in Princeton, New Jersey, focused on rapidly bringing both repurposed and new antivirals and antibiotics to market. It began working on coronavirus device and drug delivery solutions in January 2020, aiming to provide life-saving drugs to COVID-19 victims through outpatient treatment and to commercialize antivirals and delivery systems for broad global accessibility.

clinical developmentlicensing and technology transfermedicinal chemistry and drug discoveryproject managementRegulatory Affairsrespiratory drug delivery

Banner Life Sciences is an entrepreneurial specialty pharmaceutical company that combines formulation expertise with proprietary technologies to create specialty pharmaceuticals addressing unmet clinical needs. It develops medicines and drug-development strategies aimed at regulatory approval, and is now a Cycle Pharmaceuticals company following a January 2025 acquisition. Its product BAFIERTAM (monomethyl fumarate) is a disease-modifying therapy for relapsing forms of MS.

formulation expertiseproprietary technologies

Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company developing a first-in-class biologic therapy targeting fundamental drivers of solid tumor progression. Its lead program, BXQ-350, is a novel modulator of sphingolipid metabolism designed to selectively target dysregulated sphingolipids common in tumor cells, with encouraging Phase 1b/2a data in metastatic colorectal cancer.

clinical-stage biopharmaceutical researchoncology therapeutics

BioCorRx Inc. is a healthcare solutions company focused on improving the lives of those struggling with alcohol, opioid and other addictive disorders. Its Beat Addiction Recovery Program is an outpatient medication-assisted treatment program combining proprietary cognitive behavioral therapy (CBT) modules with peer recovery support. Its UnCraveRx Weight Loss Program is a medication-assisted weight loss program with virtual wellness specialists. BioCorRx Pharmaceuticals Inc. is a clinical stage drug development subsidiary developing treatments for opioid/

clinical-stage pharmaceutical developmentcognitive behavioral therapyMedication Assisted Treatmentpeer recovery support

BioCryst is a commercial-stage global biotechnology company founded in 1986, headquartered in Durham, North Carolina, with a regional office in Boston, Massachusetts. It focuses on drug discovery, development, and commercialization of oral small-molecule and injectable protein therapeutics for hereditary angioedema (HAE) and other rare diseases.

clinical trialscommercializationdrug discovery

BioLink is a specialty pharmaceutical company focused on the development and commercialization of patented treatments to meet the needs of underserved patient populations. It builds on reformulations of gold standards of care to provide novel treatments eligible for approval using 505(b)(2) New Drug Applications. Its product Phosveda addresses management of hyperphosphatemia in ESRD/dialysis patients.

505(b)(2) New Drug Applicationscommercialization of patented treatmentsreformulation of standard of care treatments

Biolytx Pharmaceuticals is an emerging drug development company confronting the crisis in antibiotic drug resistance through the advancement of a suite of antimicrobial peptide drug candidates for the treatment of serious pathogens with no current therapeutic options. Its core technology is the development of a novel antibiotic peptide for use in treatment of serious hospital-acquired infections, including those resistant to current antibiotics.

peptide developmentpre-clinical trials

Biomimesis AI Inc. is a biotechnology company focused on drug development and human biology. It develops body-on-a-chip systems designed to mimic human biology for more effective drug testing, aiming to drive innovation at the intersection of technology and biology.

body-on-a-chip technologydrug testing

Biom Pharma is an early-stage biotech founded by Bobban Subhadra, dedicated to increasing human longevity with high quality of life. It focuses on developing true-to-label nutritional supplements, novel microbiome services, and therapeutic modalities against Alzheimer's-like diseases, using designer drug products that harness a patient's own microbiome to target various disease and pathological conditions. The company develops clinical-based microbiome technologies and services to address metabolic and immune diseases.

microbiome technology platformresearch and development

BioSRQ is an accredited biotechnology company based in Sarasota, Florida. Its team has decades of science, research, and business expertise and experience navigating the drug development landscape. BioSRQ assists at any stage of the product development cycle, from concept to clinic, and works to advance drug and nutraceutical therapies efficiently and cost effectively.

product developmentscientific research

RockGen Therapeutics is a start-up biotechnology pharmaceutical company developing treatments for neurodegenerative diseases. It uses cutting-edge research into central nervous system diseases to develop novel, disease-modifying medicines, with Amyotrophic Lateral Sclerosis (ALS) as its first target, and broader efforts on Alzheimer's, Parkinson's, Huntington's, and other neurodegenerative disorders. Its pre-clinical work focuses on an anti-aggregating class of drugs.

innovative chemistryin silico systemspre-clinical researchwet laboratory systems

BridgeBio Pharma, Inc. is a biotechnology company focused on developing medicines for genetic conditions. It operates a decentralized hub-and-spoke model called The Bridge Way, in which autonomous affiliate teams focus on specific conditions or drug candidates while a central hub provides clinical, regulatory, and commercial capabilities. Its pipeline includes approved products Attruby (acoramidis) and NULIBRY (fosdenopterin), plus investigational candidates such as encaleret, BBP-418, and infigratinib.

academic research partnershipsclinical developmentclinical trialscommercial capabilitiesregulatory capabilities

BrYet is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment and cure of otherwise incurable cancers, particularly metastatic cancers of the lungs and liver. It targets cancer-specific molecular transport phenotypes using multi-component therapeutics. Its first drug, ML-016, has demonstrated functional cures in preclinical animal models. Its research is protected by a patent portfolio, some licensed from Houston Methodist Research Institute and University of Texas Health Science Center at Houston.

phenotype targetingpreclinical research

Camino Pharma is a San Diego-based startup company focused on discovering and developing first-in-class therapies for patients suffering from cancer and CNS disorders. They target signaling proteins based on emerging biological concepts and discover novel mechanisms for modulating these targets with small molecule drugs.

drug discoverysmall molecule drug discoverytarget biology

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation and is being evaluated in clinical trials for pericarditis, myocarditis, and heart failure. The company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease.

clinical developmentclinical trialsresearch and development

CartilaGen is developing CG-001, an investigational intra-articular injection therapy designed to address oxidative stress following ankle fractures and other traumatic skeletal injuries, with the goal of reducing the risk of Post-Traumatic Osteoarthritis (PTOA). CG-001 is administered during standard ORIF surgery and is designed to block excess reactive oxidant species (ROS) that drive cartilage degeneration. A Phase 1 trial has been completed with no adverse safety findings, and Department of Defense funding has been secured to support planning of a Ph

clinical developmentintra-articular injectionPTOA prevention research

Cayuga Biotech is a biopharmaceutical company developing first-in-class therapeutics that harness the body's innate ability to stop bleeding, aiming to address life-threatening hemorrhage including noncompressible hemorrhage and coagulation dysfunction. The company was founded to address significant unmet need using proprietary biomimetic science. Its founder invented CAY001.

drug discoveryhemostasis and thrombosis research

CCKr Therapeutics is a drug development company focused on transforming GI cancer and fibrosis treatment. Its lead asset, Proglumide, is a small molecule repurposed drug with oral bioavailability that antagonizes the CCK-B receptor and blocks CCK-A and CCK-B receptors. Target indications include pancreatic cancer, chronic pancreatitis, liver fibrosis, and pain management. The company reports early Phase 1 results and ongoing Phase 1/2 trials, with fast-track potential.

clinical trials (Phase 1/2)regulatory strategy

Centrexion Therapeutics is a biopharmaceutical company building a portfolio in two categories: non-opioid pain relief and immunology. Led by an experienced management team and board, the company focuses on markets with significant unmet need and partners with organizations such as Lilly, Boehringer Ingelheim, and NIH. Centrexion is headquartered at One Boston Place, Suite 3520, Boston, MA 02108.

Cerepeut is a biotechnology company developing first-in-class oral small molecule therapeutics that target mitochondrial reverse electron transport (RET) to treat neurodegeneration and age-related disease. Its lead drug candidate, CP-235, is a small molecule inhibitor of RET designed to restore mitochondrial balance and reduce oxidative stress.

small molecule drug R&D

CervoMed is a clinical stage biotechnology company focused on developing treatments for age-related neurologic disorders. Its lead product candidate, neflamapimod, is an investigational, orally administered, small molecule brain penetrant that inhibits the protein kinase p38 alpha, and is in clinical development for neurodegenerative diseases such as dementia with Lewy bodies, frontotemporal dementia and recovery after stroke. Until August 2023, CervoMed was known as EIP Pharma Inc., now a wholly-owned subsidiary.

clinical developmentcommercialization of drug treatments